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Spencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular InterventionsY ou will notice that, in January, we are publish-ing a second issue of JACC: CardiovascularInterventions. The purpose of this issue is to
focus on interesting developments in the interven-
tional approach to ST-segment elevation myocardial
infarction (STEMI). There can be no argument that the
greatest contribution of interventional cardiology
thus far is the dramatic impact on the outcomes of
myocardial infarction. Mortality rates for STEMI have
come down in many hospitals to the low single digits.
In addition, the long-term consequences of myo-
cardial infarction that were common a few years
ago, such as ventricular aneurysm development and
congestive heart failure, are now few. There is no
doubt that primary angioplasty has become a true
disruptive technology that has completely altered the
course of acute myocardial infarction. With the
progress that has been made, however, there remain
questions to be resolved in the management of
myocardial infarction. We receive excellent papers
reﬂecting the important investigations that continue
to affect outcomes. Therefore, we decided to publish
some of these studies in a special edition to accom-
plish 2 things: to get them to the readership in a more
expedited manner, and to enable reﬂection on a
number of questions related to STEMI and primary
angioplasty.
Some of the areas addressed in this issue are: a
current assessment in the progress made in applying
primary percutaneous coronary intervention (PCI)
broadly in the United States; the optimal antiplatelettherapy to accompany primary angioplasty; the value
of prophylactic warfarin anticoagulation for large
anterior myocardial infarctions; the hot question
of whether to stent nonculprit lesions at the time
of primary PCI; the strategy for managing patients
who have received ﬁbrinolysis and are eligible for
PCI; approaches to infarct size reduction, including
remote ischemic conditioning; the complication of
stent thrombosis after primary PCI; the role for the
bioabsorbable vascular scaffold in primary PCI; and
the hotly-discussed topic of anticoagulation with
heparin or bivalirudin for primary PCI. We conclude
with a spirited discussion of this topic presenting
different points of view.
We will be interested to know whether you ﬁnd
value in a concentrated emphasis on 1 aspect of
interventional cardiology. There are numerous sub-
jects similar to acute myocardial infarction that can
be explored in special issues. We have received
approval from our publisher to repeat this special
issue initiative, so you can anticipate another in April.
The subject is yet to be determined, but the effect
will be to enable us to publish some additional papers
this year. With an acceptance rate for original
research currently below 10%, we are pleased to be
able to bring more deserving papers to you.
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